Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: An open study

International Journal of Psychiatry in Clinical Practice

Volumn 8, Issue 4, 2004, Pages 255-258

  Tsukamoto, Tohru ^a   Kondoh, Reiko ^a   Ichikawa, Keiko ^a  

^a St Mary's Tsukamoto Clinic   (Japan)

Author keywords

Anxiety symptoms; Generalised anxiety disorder; Milnacipran; Noradrenaline; Serotonin

Indexed keywords

MILNACIPRAN;

ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; NAUSEA; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; SYMPTOM; VISUAL ANALOG SCALE;

EID: 10044292982     PISSN: 13651501     EISSN: None     Source Type: Journal    
DOI: 10.1080/13651500410005649     Document Type: Article

References (11)

1. Allgulander C, Bandelow B, Hollander E, Montgomery SA, Nutt DJ, Okasha A, Pollack MH, Stein DJ, Swinson RP (2003) WCA recommendations for the long-term treatment of generalized anxiety disorder. CNS Spectr 8 (Suppl 1): 53-61.
2. Rickels K, Zaninelli R, McCafferty J, Bellew K, Iyengar M, Sheehan D (2003) Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160: 749-56.
3. Lenox-Smith AJ, Reynolds A (2003) A double-blind, randomised, placebo controlled study of venlafaxine XL in patients with generalised anxiety disorder in primary care. Br J Gen Pract 53: 772-7.
4. Moret C, Charveron M, Finberg JP, Couzinier JP, Briley M (1985) Biochemical profile of midalcipran (F 2207), 1-phenyl-1-diethyl-aminocarbonyl-2- aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth generation antidepressant drug. Neuropharmacology 24: 1211-9.
5. Puech A, Montgomery SA, Prost JF, Solles A, Briley M (1997) Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 12: 99-108.
6. Gorman JM (2000) Generalized Anxiety Disorder. Clin Cornerstone 3: 37-46.
7. Marcin MS, Nemeroff CB (2003) The neurobiology of social anxiety disorder: the relevance of fear and anxiety. Acta Psychiatr Scand Suppl 417: 51-64.
8. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48: 157-62.
9. Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM, Curtis GC (1990) Adrenergic status in anxiety disorders: platelet alpha 2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28: 3-20.
10. Moret C, Briley M (1992) Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology 31: 679-84.
11. Moret C, Briley M (1997) Effects of milnacipran and pindolol on extracellular noradrenaline and serotonin levels in guinea pig hypothalamus. J Neurochem 69: 815-22.